CereVasc

Executive Summary

CereVasc is a private medical device company based in Burlington, Massachusetts, focused on developing the eShunt® System, a minimally invasive endovascular approach for treating communicating hydrocephalus. Founded in 2015, the company aims to improve patient outcomes and reduce the cost of surgical CSF shunting. The eShunt is designed to be implanted via the venous system, potentially offering a safer alternative to traditional ventricular shunts. While still in development, the technology addresses a large unmet need in neurosurgery. CereVasc has not disclosed funding or valuation details, but its innovative approach positions it as a notable player in the neurovascular space. Near-term catalysts include clinical trial enrollment milestones and potential regulatory submissions. Given the early stage, conviction is moderate pending clinical data.

Upcoming Catalysts (preview)

• Q2 2027Completion of Pivotal Clinical Trial Enrollment60% success
• Q4 2026FDA IDE Approval for Expanded Study75% success
• Q3 2026Presentation of Early Feasibility Study Results80% success